Trial Profile
STUDY OF PALBOCICLIB IN COMBINATION WITH LETROZOLE AS TREATMENT OF POSTMENOPAUSAL WOMEN WITH HORMONE RECEPTOR POSITIVE, HER2-NEGATIVE ADVANCED BREAST CANCER FOR WHOM LETROZOLE THERAPY IS DEEMED APPROPRIATE
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 22 Aug 2023
Price :
$35
*
At a glance
- Drugs Letrozole (Primary) ; Palbociclib (Primary)
- Indications Adenocarcinoma; Advanced breast cancer; HER2 negative breast cancer
- Focus Adverse reactions; Expanded access; Registrational
- Sponsors Pfizer
- 18 Aug 2023 Results published in the Clinical Drug Investigation
- 13 Jun 2019 Status changed from active, no longer recruiting to completed.
- 24 May 2019 Planned End Date changed from 31 Mar 2019 to 30 May 2019.